CJC-1295 vs Hexarelin
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
CJC-1295
CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) analog. It stimulates the pituitary gland to release growth hormone and is almost universally used in combination with a GHRP like Ipamorelin to produce a more physiological GH pulse.
Full profileHexarelin
Hexarelin is a potent synthetic hexapeptide GHRP (Growth Hormone-Releasing Peptide) that stimulates GH release via the ghrelin receptor. It produces among the highest GH pulses of any GHRP, but also elevates cortisol and prolactin — a trade-off that distinguishes it from more selective options like Ipamorelin.
Full profile| CJC-1295 | Hexarelin | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | CJC-1295 DAC, CJC-1295 without DAC (Mod GRF 1-29), Modified GRF 1-29 | Examorelin, EP 23905, MF-6003 |
| Evidence | Research-stage | Preclinical only |
| Dosing range | 100mcg–300mcg mcg, once daily (Mod GRF) or twice weekly (DAC version) | 50mcg–200mcg mcg, 1–3x daily (cycling recommended to prevent desensitization) |
| Administration | Subcutaneous injection (most common), Intramuscular injection | Subcutaneous injection, Intramuscular injection |
| Key side effects | Water retention (especially early in protocol), Tingling or numbness in extremities, Injection site redness, Flushing (transient, shortly after injection) | Cortisol elevation, Prolactin elevation, Water retention, Increased appetite |
| Cited sources | 2 references | 1 reference |
Key differences
- Evidence level differs: CJC-1295 is research-stage, while Hexarelin is preclinical only.
- Administration: CJC-1295 — Subcutaneous injection (most common), Intramuscular injection; Hexarelin — Subcutaneous injection, Intramuscular injection.
- Frequency: CJC-1295 is typically once daily (Mod GRF) or twice weekly (DAC version); Hexarelin is 1–3x daily (cycling recommended to prevent desensitization).
- Research depth: this profile cites 2 sources for CJC-1295 vs 1 for Hexarelin.
Can you stack CJC-1295 and Hexarelin?
compatible: Compatible but hexarelin has more side effect risk
This combination works via complementary pathways (GHRH + ghrelin receptor) similar to CJC/Ipamorelin, but hexarelin is significantly more potent and may raise cortisol and prolactin at higher doses. Research typically favors CJC-1295 + Ipamorelin for a cleaner profile.
See the full compatibility matrixHow each works
CJC-1295
Studies have demonstrated that CJC-1295 significantly increases plasma GH and IGF-1 levels. The DAC (Drug Affinity Complex) version extends the half-life to approximately 6–8 days via albumin binding, while Mod GRF 1-29 has a much shorter half-life (~30 minutes) and is dosed more acutely. Research in adults with GH deficiency has shown improved body composition and metabolic markers.
Hexarelin
Hexarelin produces dose-dependent GH release significantly greater than GHRP-6 or Ipamorelin. It also has direct cardioprotective effects via CD36 receptor binding, independent of GH — making it unique among GHRPs. Studies show protection from ischemic cardiac injury and myocardial fibrosis reduction in animal models. Desensitization occurs with chronic continuous use.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.